Huttig Bldg Products (HBP) 5.59 $HBP Helix BioPharma

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 8:03 AM

Huttig Bldg Products (HBP) 5.59 $HBP

Helix BioPharma Corp. Closes CAD1.8 Million Private Placement
Marketwired - Fri Jul 29, 3:01PM CDT
AURORA, ON--(Marketwired - Jul 29, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.8 million.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

AACR Approves Helix BioPharma Corp's Poster for Presentation at the International Cancer Immunotherapy Conference
Marketwired - Tue Jul 26, 6:15AM CDT
Urease-Mediated Alkalization of Tumor Microenvironment and Its Effects on T Cell Proliferation, Cytokine Release and PD-1/PD-L1 Interactions
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Helix BioPharma Corp. Announces Agreement in Principle With National Research Council of Canada to Collaborate on Various Immuno-Oncology Initiatives
Marketwired - Mon Jul 18, 3:10PM CDT
AURORA, ON--(Marketwired - Jul 18, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that an Agreement in Principle ("Agreement"

has been reached with the National Research Council of Canada ("NRC"

to collaborate on various immuno-oncology initiatives.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Helix BioPharma Corp. Appoints Evolution Life Science Partners as Advisors
Marketwired - Thu Jun 02, 7:00AM CDT
AURORA, ON--(Marketwired - Jun 2, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Evolution Life Science Partners to act as advisors to the Company. Activities the Company may pursue could include, but are not limited to, partnering or other collaboration agreements. The Company does not intend to disclose developments with respect to this process except as required under applicable securities regulations.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Huttig Adopts Rights Plan to Protect Net Operating Loss Carryforwards
Marketwire Canada - Thu May 19, 3:30PM CDT
ST. LOUIS, MO --(Marketwired - May 19, 2016) - Huttig Building Products, Inc. ("Huttig"

(NASDAQ: HBP) today announced that its Board of Directors has adopted a rights plan as a measure to protect the Company's existing net operating loss carryforwards ("NOLs"

and preserve the Company's ability to use its NOLs to offset future taxable income, without limitation. As of March 31, 2016, the Company had Federal NOL carryforwards of approximately $55 million. The Company intends to seek stockholder approval of the rights plan at its 2017 Annual Meeting of Stockholders.
HBP: 5.59 (+0.03)

First Patient Dosed in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Wed May 11, 6:30AM CDT
AURORA, ON--(Marketwired - May 11, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient was dosed in the Phase II component of study LDOS002.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Helix BioPharma Corp. Subsidiary, Helix Polska Sp zo.o., Qualifies for CAD4.1 Million Grant From the Polish National Center for Research and Development
Marketwire Canada - Mon May 09, 6:30AM CDT
AURORA, ON--(Marketwired - May 9, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that its wholly owned subsidiary, Helix Polska Sp. z o.o. qualifies for a grant of approximately PLN12.5mil from the Polish National Centre for Research and Development to develop V-DOS47 in breast cancer. The acceptance of the grant is subject to review and approval of the final terms and conditions by Helix's management and Board of Directors and may be subject to conditions imposed by the granting authority and corporate or other approvals.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Huttig posts 1Q profit
Automated Insights - Mon May 02, 3:57PM CDT
ST LOUIS (AP) _ Huttig Building Products Inc. (HBP) on Monday reported profit of $1.4 million in its first quarter.
HBP: 5.59 (+0.03)

Huttig Building Products, Inc. Announces First Quarter 2016 Results
Marketwired - Mon May 02, 3:30PM CDT
First Quarter 2016 Highlights:
HBP: 5.59 (+0.03)

Helix BioPharma Corp. Closes CAD4.7 Million Private Placement Financing
Marketwired - Fri Apr 29, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD4.7 million.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

First Patient Enrolled in Phase II Study of L-DOS47 in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 28, 6:30AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the first patient has been enrolled in the Phase II component of study LDOS002.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Trial Steering Committee Recommends Initiation of Phase II L-DOS47 Study in Non-Small Cell Lung Cancer
Marketwire Canada - Thu Apr 21, 4:00AM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a clinical stage biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the recommendation by the Trial Steering Committee to initiate the Phase II component of the LDOS002 study.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Helix BioPharma Corp. Announces Important Additions to Its Leadership Team
Marketwire Canada - Wed Apr 20, 6:30PM CDT
Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"

, a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the appointment of Dr. Patrick Frankham to Chief Operating Officer and the promotion of Mr. Steve Demas to the position of Chief Medical Officer. Dr. Frankham and Mr. Demas will both report directly to Dr. Sven Rohmann, Helix's newly appointed Chief Executive Officer.
HBP: 5.59 (+0.03), HBP.TO: 2.00 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Skiptown Expands in Georgia Amid Growing Demand

With the pet care industry barking up a storm lately, Skiptown is ramping up efforts to expand its presence in Georgia. The tech-enabled dog care franchise already has a paw print in Atlanta, but it's sniffing out new opportunities across the state. Now they're on the hunt for franchise owners who can bring this modern approach to more communities. Why Georgia? The Growth...

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Montessori and Tech: A New Era of Integration

Reimagining Montessori with Technology Let's take a stroll down the road less traveled—the intersection of Montessori education and tech. For over a century, Montessori schools have valued individual child development, autonomy, and a purpose-driven environment. But let's face it, their technology hasn't always had the same handcrafted finesse. That's where illumine...

Canada and Ukraine Fortify Defense with UGV Partnership

New Defense Fronts: Canada and Ukraine Join Forces October 13, 2026, marks an important day in Ottawa's defense narrative with Dominion Dynamics and Ukraine's TENCORE kicking off a robust partnership. They're not just collaborating; they're plugging into each other's strengths to build TerMIT uncrewed ground vehicles (UGVs) on Canadian soil. These aren't gizmos you find...